Semicarbazide-Sensitive Amine Oxidases: Enzymes with Quite a Lot to Do

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 303-315

  O'Sullivan, Jeff ^a   Unzeta, Mercedes ^b   Healy, Joe ^a   O'Sullivan, Michael I ^a   Davey, Gavin ^a   Tipton, Keith F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Aldehyde; Amiloride binding protein; Diabetes; GLUT 4; Hydrogen peroxide; Monoamine oxidase; Semicarbazide sensitive amine oxidase (SSAO); VAP 1; Vascular adhesion; Xenobiotic

Indexed keywords

2 (3,4 DIMETHOXYPHENYL) 3 FLUOROALLYLAMINE; 2 BROMOETHYLAMINE; 4 AMINOMETHYL 3,5 DIETHOXYPYRIDINE; ACETONE; ACROLEIN; ALDEHYDE; AMILORIDE; AMINE OXIDASE (COPPER CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BENZYLAMINE; CYANIDE; DOPAMINE; FORMALDEHYDE; HYDRAZINE DERIVATIVE; HYDROGEN PEROXIDE; MESCALINE; METHYLAMINE; METHYLHYDRAZINE; MONOAMINE OXIDASE B INHIBITOR; PENTYLAMINE; PHENETHYLAMINE; PRIMAQUINE; PROCARBAZINE; SEMICARBAZIDE; SEROTONIN; TYRAMINE; UNINDEXED DRUG; VASCULAR ADHESION PROTEIN 1; XENOBIOTIC AGENT;

AORTA; CELL ADHESION; CELL MATURATION; DEAMINATION; DRUG BINDING; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME SUBSTRATE; GLUCOSE HOMEOSTASIS; INFLAMMATION; LIPID TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 0347415714     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00117-7     Document Type: Article

References (116)

1. Alton G, Taher TH, Beever RJ, Palcic MM. Stereochemistry of benzylamine oxidation by copper amine oxidases. Arch Biochem Biophys 1995;353-61.
2. Andrés N, Lizcano JM, Rodríguez MJ, Romera M, Unzeta M, Mahy N. Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. J Histochem Cytochem 2001;49:209-17.
3. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty KRH. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 1993;18:1175-7.
4. Arvilommi AM, Salmi M, Jalkanen S. Organ-selective regulation of vascular adhesion protein-1 expression in man. Eur J Immunol 1997;27:1794-800.
5. Boomsma F, Derkx FH, van den Meiracker AH, Man in't Veld AJ, Schalekamp MADH. Plasma semicarbazide-sensitive amine oxidase is elevated in diabetes mellitus and correlates with glycosylated haemogloblin. Clin Sci (Lond) 1995;88:675-9.
6. Boomsma F, van Veldhuisen DJ, de Kam PJ, Man in 't Veld AJ, Mosterd A, Lie KI et al. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 1997;33:387-91.
7. Boomsma F, van Dijk J, Bhaggoe UM, Bouhuizen AM, van den Meiracker AH. Variation in semicarbazide-sensitive amine oxidase activity in plasma and tissues of mammals. Comp Biochem Physiol C: Pharmacol Toxicol Endocrinol 2000a; 126:69-78.
8. Boomsma F, de Kam PJ, Tjeerdsma G, van den Meiracker AH, van Veldhuisen DJ. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur Heart J 2000;21:1859-63.
9. Buffoni F. Histaminase and related amine oxidases. Pharmacol Rev 1966;18:1163-99.
10. Buffoni F, Della Corte L. Pig plasma benzylamine oxidase. Adv Biochem Psychopharmacol 1972;5:133-49.
11. Buffoni F, Banchelli G, Ignesti G, Pirisino R, Raimondi L. The presence of an inhibitor of benzylamine oxidase in human blood plasma. Biochem J 1983;211:767-9.
12. Buffoni F, Bertini V, Dini G. The mechanism of inhibition of benzylamine oxidase by 3,5-diethoxy-4-aminomethylpyridine (B24). J Enzyme Inhib 1998;13:253-66.
13. Calabrese L, Carbonaro M, Musci G. Presence of coupled trinuclear copper cluster in mammalian ceruloplasmin is essential for efficient electron transfer to oxygen. J Biol Chem 1989;264:6183-7.
14. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 1998;32:117-31.
15. Cai D, Williams NK, Klinman JP. Effect of metal on 2,4,5-trihydroxyphenylalanine (topa) quinone biogenesis in the Hansenula polymorpha copper amine oxidase. J Biol Chem 1997;272:19277-81.
16. Callingham BA, McCarry WJ, Barrand MA. Effects of some carbonyl reagents and short-acting MAO inhibitors on semicarbazide-sensitive (clorgyline-resistant) amine oxidase in the rat. In: Tipton KF, Dostert P, Strolin Benedetti M, editors. Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press; 1984. p. 595-96.
17. Callingham BA, Crosbie AE, Rous BA. Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. Prog Brain Res 1995;106:305-21.
18. Cronin CN, Zhang X, Thompson DA, McIntire WS. cDNA cloning of two splice variants of a human copper-containing monoamine oxidase pseudogene containing a dimeric Alu repeat sequence. Gene 1998;220:71-6.
19. Castillo V, Lizcano JM, Unzeta M. Presence of SSAO in human and bovine meninges and microvessels. Neurobiology 1999;7:263-72.
20. Conklin DJ, Langford SD, Boor PJ. Contribution of serum and cellular semicarbazide-sensitive amine oxidase to amine metabolism and cardiovascular toxicity. Toxicol Sci 1998;46:386-92.
21. Dalfó E, Hernandez M, Lizcano JM, Tipton KF, Unzeta M. Activation of human lung semicarbazide sensitive amine oxidase (SSAO) by a low molecular weight component present in human plasma. Biochim Biophys Acta 2003;1638:278-86.
22. Dutra F, Knudsen FS, Curi D, Bechara EJH. Aerobic oxidation of aminoacetone, a threonine catabolite: iron catalysis and coupled iron release from ferritin. Chem Res Toxicol 2001;14:1323-9.
23. Ekblom J, Gronvall JL, Garpenstrand H, Nillson S, Oreland L. Is semicarbazide-sensitive amine oxidase in blood plasma partly derived from the skeleton? Neurobiology 2000;8:129-35.
24. El Hadri K, Moldes M, Mercier N, Andreani M, Pairault J, Feve B. Semicarbazide-sensitive amine oxidase in vascular smooth muscle cells. Differentiation-dependent expression and role in glucose uptake. Arterioscler Thromb Vasc Biol 2002;22:89-94.
25. Elliott J, Callingham BA, Barrand MA. In vivo effects of (E)-2-(3′,4′-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Selective inhibition of semicarbazide-sensitive amine oxidase in vascular and brown adipose tissues. J Pharm Pharmacol 1989a;41:37-41.
26. Elliott J, Callingham BA, Sharman DF. Metabolism of amines in the isolated perfused mesenteric bed of the rat. Br J Pharmacol 1989b;98:507-14.
27. Elliott J, Callingham BA, Sharman DF. Amine oxidase enzymes of sheep blood vessels and blood plasma: A comparison of their properties. Comp Biochem Physiol C: Pharmacol Toxicol Endocrinol 1992;102:83-9.
28. Enrique-Tarancon G, Marti L, Morin N, Lizcano JM, Unzeta M, Sevilla L et al. Role of semicarbazide-sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell-surface in adipose cells. J Biol Chem 1998;273:8025-32.
29. Enrique-Tarancon G, Castan I, Morin N, Marti L, Abella A, Camps M et al. Substrates of semicarbazide-sensitive amine oxidase co-operate with vanadate to stimulate tyrosine phosphorylation of insulin-receptor-substrate proteins, phosphoinositide 3-kinase activity and GLUT4 translocation in adipose cells. Biochem J 2000;350:171-80.
30. Exner M, Hermann M, Hofbauer R, Kapiotis S, Quehenberger P, Speiser W et al. Semicarbazide-sensitive amine oxidase catalyzes endothelial cell-mediated low density lipoprotein oxidation. Cardiovasc Res 2001;50:583-8.
31. Ferrer I, Lizcano JM, Hernandez M, Unzeta M. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett 2002;321:21-4.
32. Fitzgerald DH, Tipton KF. Inhibition of monoamine oxidase modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO). J Neural Transm 2002;109:251-65.
33. Fontana E, Boucher J, Marti L, Lizcano JM, Testar X, Zorzano A et al. Amine oxidase substrates mimic several of the insulin effects on adipocyte differentiation in 3T3 F442A cells (2001). Biochem J 2001;356:769-77.
34. Garpenstrand H, Ekblom J, Backlund LB, Oreland L, Rosenqvist U. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in type 2 diabetes mellitus complicated by retinopathy. Diabet Med 1999a;16:514-21.
35. Garpenstrand H, Ekblom J, von Arbin M, Oreland L, Murray V. Plasma semicarbazide-sensitive amine oxidase in stroke. Eur Neurol 1999b;41:20-3.
36. Gewitz MH, Gillis CN. Uptake and metabolism of biogenic amines in the developing rabbit lung. J Appl Physiol 1981;50:118-22.
37. Gronvall-Nordquist JL, Backlund LB, Garpenstrand H, Ekblom J, Landin B, Yu PH et al. Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in type 2 diabetes mellitus (2001). J Diabet Complic 2001;15:250-6.
38. Hasan F, Mc Crodden JM, Kennedy NP, Tipton KF. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm 1998;26(Suppl): 1-9.
39. Heck HD, Casanova M, Starr TB. Formaldehyde toxicity-new understanding. Crit Rev Toxicol 1990;20:397-426.
40. Holt A, Callingham BA. Further studies on the ex vivo effects of procarbazine and monomethylhydrazine on rat semicarbazide-sensitive amine oxidase and monoamine oxidase activities. J Pharm Pharmacol 1995;47:837-45.
41. Holt AG, Alton G, Scaman CH, Loppnow GR, Szpacenko A, Svendsen I et al. Identification of the quinone cofactor in mammalian semicarbazide-sensitive amine oxidase. Biochemistry 1998;37:4946-57.
42. Houen G. Mammalian Cu-containing amine oxidases (CAOs): new methods of analysis, structural relationships, and possible functions. APMIS 1999;96:1-46.
43. Imamura Y, Kubota R, Wang Y, Asakawa S, Kudoh J, Mashima Y et al. Human retina-specific amine oxidases (RAO): cDNA cloning, tissue expression and chromosomal mapping. Genomics 1997;40:277-83.
44. Jalkanen S, Salmi M. Cell-surface monoamine oxidases: enzymes in search of a function. EMBO J 2001;20:3893-901.
45. Janes SM, Klinman JP. Isolation of 2,4,5-trihydroxyphenylalanine quinone (topa quinone) from copper amine oxidases. Meth Enzymol 1995;258:20-34.
46. Karádi I, Mészáros Z, Csányi A, Szombathy T, Hosszúfalusi L, Romics L et al. Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin Chim Acta 2002;323:139-46.
47. Klinman JP, Mu D. Quinoenzymes in biology. Ann Rev Biochem 1994;63:299-344.
48. Knowles PF, Yadav KDS. In: Lontie R, editor. Amine oxidases. Copper proteins and copper enzymes, vol. II. Flordia: CRC Press; 1984. p. 103-29.
49. Kurkijärvi R, Adams DH, Leino R, Mottonen T, Jalkanen S, Salmi M. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 1998;161:1549-57.
50. Kurkijärvi R, Jalkanen S, Isoniemi H, Salmi M. Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. Eur J Immunol 2001;31:2876-84.
51. Kinemuchi H, Jinbo M, Tabata A, Toyoshima Y, Arai Y, Tadano T et al. 2-Bromoethylamine, a suicide inhibitor of tissue-bound semicarbazide-sensitive amine oxidase. Jpn J Pharmacol 2000;83:164-6.
52. Langford SD, Trent MB, Balakumaran A, Boor PJ. Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase. Toxicol Appl Pharmacol 1999;155:237-44.
53. Langford SD, Trent MB, Boor PJ. Semicarbazide-sensitive amine oxidase and extracellular matrix deposition by smooth-muscle cells. Cardiovasc Toxicol 2002;2:141-50.
54. Lewinsohn R. Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. Braz J Med Biol Res 1984;17:223-56.
55. Lewinsohn R, Sandler M. Monoamine-oxidizing enzymes in human pregnancy. Clin Chim Acta 1982;120:301-12.
56. Limon-Boulez I, Tesson F, Gargalidis-Moudanos C, Parini A. I2-Imidazoline binding sites: relationship with different monoamine oxidase domains and identification of histidine residues mediating ligand binding regulation by H+1. J Pharmacol Exp Ther 1996;276:359-64.
57. Lizcano JM, Balsa D, Tipton KF, Unzeta M. Amine oxidase activities in bovine lung. J Neural Transm M 1990;32(Suppl):341-4.
58. Lizcano JM, Balsa D, Tipton KF, Unzeta M. The oxidation of dopamine by the semicarbazide-sensitive amine oxidase (SSAO) from rat vas deferens. Biochem Pharmacol 1991a;41:1107-10.
59. Lizcano JM, Escrich E, Ribalta T, Muntane J, Unzeta M. Amine oxidase activities in rat breast cancers induced experimentally with 7,12-dimethylbenz(alpha)anthracene. Biochem Pharmacol 1991b;42:263-9.
60. Lizcano JM, Fernandez de Ariba A, Tipton KF, Unzeta M. Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol 1996;52:187-95.
61. Lizcano JM, Tipton KF, Unzeta M. Purification and characterization of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. Biochem J 1998;331:69-78.
62. Lyles GA. Substrate-specificity of mammalian tissue-bound semicarbazide-sensitive amine oxidase. Progr Brain Res 1995;106:293-303.
63. Lyles GA. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int J Biochem Cell Biol 1996;28:259-74.
64. Lyles GA, Chalmers J. The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 1992;43:1409-14.
65. Lyles GA, Fitzpatrick CMS. An allylamine derivative (MDL 72145) with potent irreversible inhibitory actions on rat aorta semicarbazide-sensitive amine oxidase. J Pharm Pharmacol 1985;37:329-35.
66. Lyles GA, Marshall CMS, McDonald IA, Bey P, Palfreyman MG. Inhibition of rat aorta semicarbazide-sensitive amine oxidase by 2-phenyl-3-haloallylamines and related compounds. Biochem Pharnacol 1987;36:2847-53.
67. Marti L, Abella A, Carpene C, Palacin M, Testar X, Zorzano A. Combined treatment with benzylamine and low dosages of vanadate enhances glucose tolerance and reduces hyperglycemia in streptozotocin-induced diabetic rats. Diabetes 2001;50:2061-8.
68. Mathys KC, Ponnampalam SN, Padival S, Nagaraj RH. Semicarbazide-sensitive amine oxidase in aortic smooth muscle cells mediates synthesis of a methylglyoxal-AGE: implications for vascular complications in diabetes. Biochem Biophys Res Commun 2002;297:863-9.
69. McDonald IA, Lacoste JM, Bey P, Palfreyman MG, Zreika M. Enzyme-activated irreversible inhibition of monoamine oxidase: phenylallylamine structure-activity relationships. J Med Chem 1985;28:186-93.
70. McGuirl MA, Dooley DM. Copper-containing oxidases. Curr Opin Chem Biol 1999;3:138-44.
71. Mercier N, Moldes M, El Hadri K, Feve B. Semicarbazide-sensitive amine oxidase activation promotes adipose conversion of 3T3-L1 cells. Biochem J 2001;303:335-42.
72. Mercier N, Moldes M, Hadri KE, Feve B. Regulation of semicarbazide-sensitive amine oxidase expression by tumor necrosis factor-alpha in adipocytes: functional consequences on glucose transport. J Pharmacol Exp Ther 2003;304:1197-208.
73. Meszaros Z, Szombathy T, Raimondi L, Karadi I, Romics L, Magyar K. Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 1999;48:113-7.
74. Moldes M, Fève B, Pairault J. Molecular cloning of a major mRNA species in murine 3T3 adipocyte lineage: differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase. J Biol Chem 1999;274:9515-23.
75. Morgan DM. Polyamine oxidases. Biochem Soc Trans 1985;13:322-6.
76. Morin N, Lizcano JM, Fontana E, Marti L, Smih F, Rouet P et al. Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes. J Pharmacol Exp Ther 2001;297:563-72.
77. Mu D, Medzihradsezky KF, Adams GW, Mayer P, Hiness WM, Burlingames AL et al. Primary structures for a mammalian cellular and serum copper amine oxidase. J Biol Chem 1994;269:9926-32.
78. Nilsson SE, Tryding N, Tufvesson G. Serum monoamine oxidase in diabetes mellitus and some other internal diseases. Acta Med Scand 1968;184:105-8.
79. Nocera S, Marcocci L, Pietrangeli P, Mondovi B. New perspectives on the role of amine oxidases in physiopathology. Amino Acids 2003;24:13-7.
80. Nordqvist A, Oreland L, Fowler CJ. Some properties of monoamine oxidase and a semicarbazide sensitive amine oxidase capable of the deamination of 5-hydroxytryptamine from porcine dental pulp. Biochem Pharmacol 1982;31:2739-44.
81. Nordquist JE, Gokturk C, Oreland L. Semicarbazide-sensitive amine oxidase gene expression in alloxan-induced diabetes in mice. Mol Med 2002;8:824-9.
82. Novotny WF, Chassande O, Baker M, Lazdunski M, Barbry P. Diamine oxidase is the amiloride-binding protein and is inhibited by amilorideanalogues. J Biol Chem 1994;269:9921-5.
83. O'Sullivan M, Tipton KF, McDevitt WE. Immunolocalization of semicarbazide-sensitive amine oxidase in human dental pulp and its activity towards serotonin. Arch Oral Biol 2002;47:399-406.
84. O'Sullivan J, O'Sullivan M, Tipton KF, Unzeta M, Hernandez M, del M et al. The inhibition of semicarbazide-sensitive amine oxidase by aminohexoses. Biochim Biophys Acta 2003a;1647:367-71.
85. O'Sullivan M, MacDougall MB, Unzeta M, Lizcano JM, Tipton KF. Semicarbazide-sensitive amine oxidases in pig dental pulp. Biochim Biophys Acta 2003b;1647:333-6.
86. Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G. Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential. J Neural Transm 1994;41(Suppl): 407-14.
87. Precious E, Gunn CE, Lyles GA. Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem Pharmacol 1988;37:707-13.
88. Raimondi L, Pirisino R, Banchelli G, Ignesti G, Conforti L, Buffoni F. Cultured preadipocytes produce a semicarbazide-sensitive amine oxidase (SSAO) activity. J Neural Transm 1990;331-36.
89. Ramos KSL, Grossman SL, Cox LR. Allylamine-induced vascular toxicity in vitro: prevention by semicarbazide-sensitive amine oxidase inhibitors. Toxicol Appl Pharmacol 1988;95:61-71.
90. Rydén L. Ceruloplasmin. In: Lontie, L, editor. Copper proteins and copper enzymes copper proteins and copper enzymes. Boca Raton FL, USA: CRC Press; 1984. p. 37-100.
91. Salmi M, Hellman J, Jalkanen S. The role of two distinct endothelial molecules, vascular adhesion protein-1 and peripheral lymph node addressin, in the binding of lymphocyte subsets to human lymph nodes. J Immunol 1998;160:5629-36.
92. Salmi M, Tohka S, Jalkanen S. Human vascular adhesion protein-1 (VAP-1) plays a critical role in lymphocyte-endothelial cell adhesion cascade under shear. Circ Res 2000;86:1245-51.
93. Salmi M, Stolen C, Jousilahti P, Yegutkin GG, Tapanainen P, Janatuinen T et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 2002;161:2255-62.
94. Salminen TA, Smith DJ, Jalkenen S, Johnson MS. Structural model of the catalytic domain of an enzyme with cell adhesion activity: human vascular adhesion protein-1 (HVAP-1). Protein Eng 1998;11:1195-204.
95. Sikkema JM, Franx A, Fijnheer R, Nikkels PG, Bruinse HW, Boomsma F. Semicarbazide-sensitive amine oxidase in pre-eclampsia: no relation with markers of endothelial cell activation. Clin Chim Acta 2002;324:31-8.
96. Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med 1998;188:17-27.
97. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 1988;16:387-98.
98. Souto RP, Vallega G, Wharton J, Vinten J, Tranum-Jensen J, Pilch PF. Immunopurification and characterization of rat adipocyte caveolae suggest their dissociation from insulin signalling. J Biol Chem 2003;278:18321-9.
99. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996;27:565-73.
100. Tipton KF, Strolin Benedetti M. Amine oxidases and the metabolism of xenobiotics. In: Ioannides C, editor. Enzyme systems that metabolise drugs and other xenobiotics. Chichester: Wiley; 2001. p. 95-146.
101. Tipton KF, Davey G, Motherway M. Monoamine oxidase assays. In: Taylor GP, Sullivan JP, editors. Current protocols in pharmacology. New York: Wiley; 2000. p. 3.6.1-42.
102. Tipton KF, O'Sullivan MI, Davey GP, O'Sullivan J. It can be a complicated life being an enzyme. Biochem Soc Trans 2003;31:711-5.
103. Tohka S, Laukkanen M-L, Jalkanen S, Salmi M. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo. FASEB J 2001;15:373-82.
104. Wang XT, Pietrangeli P, Mateescu M, Mondovi B. Extended substrate specificity of serum amine oxidase: possible involvement in protein posttranslational modification. Biochem Biophys Res Commun 1996;223:91-7.
105. Wang SX, Nakamura N, Mure M, Klinman JP, Sanders-Loeht J. Characterization of the native lysine tyrosylquinone cofactor of lysyl oxidase by Raman spectroscopy. J Biol Chem 1997;272:28841-4.
106. Wilmot CM, Murray JM, Alton G, Parsons MR, Convery MA, Blakeley V et al. Catalytic mechanism of the quinoenzyme amine oxidase from Escherichia coli: exploring the reductive half-reaction. Biochemistry 1997;36:1608-20.
107. + channel currents by serum aminoxidase in neurons. Biochem Biophys Res Commun 1996;220:47-52.
108. Yang FM, Friedrichs WE, Cupples RL, Bonifacio MJ, Sanford JA, Horton WA, Bowman BH. Human ceruloplasmin. Tissue-specific expression of transcripts produced by alternative splicing. J Biol Chem 1990;265:10780-5.
109. Yoong KF, McNab G, Hübscher SG, Adams DH. Vascular adhesion protein-1 and I-CAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998;160:3978-88.
110. Young SN, Davis BA, Gauthier S. Precursors and metabolites of phenylethylamine, m- and p-tyramine and tryptamine in human lumbar and cisternal cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1982;45:633-9.
111. Yu PH. Deamination of methylamine and angiopathy; toxicity of formaldehyde, oxidative stress and relevance to protein glycoxidation in diabetes. J Neural Transm 1998;52(Suppl):201-16.
112. Yu PH, Davis BA. Stereospecific deamination of benzylamine catalyzed by different amine oxidases. Int J Biochem 1988;20:1197-201.
113. Yu PH, Deng Y. Potential cytotoxic effect of chronic administration of creatine, a nutrition supplement to augment athletic performance. Med Hypotheses 2000;54:726-8.
114. Yu PH, Davis BA, Deng Y. 2-Bromoethylamine as a potent selective suicide inhibitor for semicarbazide-sensitive amine oxidase. Biochem Pharmacol 2001;61:741-8.
115. Zhang X, McIntire WS. Cloning and sequencing of a human copper-containing, topa quinone-containing monoamine oxidase from human placenta. Gene 1996;179:279-86.
116. Zreika M, McDonald IA, Bey P, Palfreyman MG. MDL 72145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type B. J Neurochem 1984;43:448-54.